QLGN vs. MIRA, NAII, BCTX, LGVN, JATT, BLRX, CING, MRKR, BIVI, and QTTB
Should you be buying Qualigen Therapeutics stock or one of its competitors? The main competitors of Qualigen Therapeutics include MIRA Pharmaceuticals (MIRA), Natural Alternatives International (NAII), Briacell Therap (BCTX), Longeveron (LGVN), JATT Acquisition (JATT), BioLineRx (BLRX), Cingulate (CING), Marker Therapeutics (MRKR), BioVie (BIVI), and Q32 Bio (QTTB). These companies are all part of the "pharmaceutical products" industry.
Qualigen Therapeutics vs. Its Competitors
MIRA Pharmaceuticals (NASDAQ:MIRA) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.
Qualigen Therapeutics' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.
MIRA Pharmaceuticals has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500.
35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Qualigen Therapeutics has higher revenue and earnings than MIRA Pharmaceuticals.
In the previous week, MIRA Pharmaceuticals and MIRA Pharmaceuticals both had 4 articles in the media. Qualigen Therapeutics' average media sentiment score of 1.89 beat MIRA Pharmaceuticals' score of 0.92 indicating that Qualigen Therapeutics is being referred to more favorably in the news media.
MIRA Pharmaceuticals presently has a consensus price target of $14.00, suggesting a potential upside of 648.66%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe MIRA Pharmaceuticals is more favorable than Qualigen Therapeutics.
Summary
MIRA Pharmaceuticals beats Qualigen Therapeutics on 7 of the 12 factors compared between the two stocks.
Get Qualigen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for QLGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding QLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Qualigen Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:QLGN) was last updated on 7/16/2025 by MarketBeat.com Staff
Free QLGN Stock Alerts